Glucose Sensors Take Field Advantage

Gluco-Chaser unveils a working prototype for non-enzymatic electrochemical glucose sensors, that reportedly offers multiple advantages over existing glucose sensors. The Gluco-Chaser CGM offers flexibility in choosing a platform format, cost savings in production and storage (highly affordable end user pricing), and other technical features that improve user comfort level and hygiene. Notable, the CGM can be used daily for extended periods of time, which is useful for management of both Type 1 and Type 2 diabetes. The glucose detection mechanism and the corresponding electrode preparation methods are proprietary.

 

Advantages

SENSORS EXPO & CONFERENCE

Sensors 2018 Hits Silicon Valley June 26-28!

Join thousands of engineers this June in San Jose at the sensor industry’s biggest event! With 65+ Technical Sessions, 100+ Leading Speakers, and 300+ Interactive Exhibits, there’s more opportunity than ever to connect with this booming industry and the technologies driving it. See thousands of the newest technologies in action, learn about the latest applications, including AI, Autonomous Vehicles, IoT, and Medical, and develop invaluable partnerships at the only event dedicated to sensors, connectivity, and systems.

 

Business Benefits: Unlike most glucose sensors, CGM does not require an unstable and expensive enzyme for glucose detection. This leads to huge cost savings in production and storage of the core sensing components. Gluco-Chaser technology is applicable to various formats of glucose monitors from conventional BGM to short-term (8 ~ 48 hours)- and long-term (3 ~ 7 days, and beyond) CGMs.

 

Usage Benefits: CGM offers the following features: (1) calibration-free operation of the sensor*; (2) 30-minute window for initial stabilization (competitors range anywhere from 3 to 12 hrs.); and (3) affordable pricing, comparable to that of conventional finger-prick sensors. This package of features has yet to be implemented by current market leaders, making it a smarter choice for Type-2 as well as Type-1 patients.

 

* Currently under development

 

Current achievements: (1) short initial stabilization time (30 minutes); (2) long sensor stability (immersed in human plasma for 1 month); (3) animal testing (EGA A+B > 90%); (4) elimination of noise from major interferents such as ascorbic acid, acetaminophen, and maltose; (5) BGM strip sensor under development (Whole blood tested; EGA A+B = 98%; journal publication in press).

 

For more top-secret info, contact Peter Lee via email at either [email protected] or [email protected] or go old school and call on the phone via +1-425-625-6724.